<DOC>
	<DOCNO>NCT02466438</DOCNO>
	<brief_summary>Severe infection one main cause disease hospitalized child deadly . With lack novel antibiotic approve child emergence drug resistant bacteria , critical need optimize dose exist antibiotic . Piperacillin-tazobactam antibiotic frequently use treatment severe infection child Canadian hospital . To optimize antibiotic 's efficacy despite rise antibiotic resistance , alternative dosing strategy commonly use adult , consist prolonging time drug infuse ( 4 hour instead 30 min ) . Children clear piperacillin-tazobactam body slower rate adult , consequently extended-infusion strategy directly extrapolate adult child . We believe young child need piperacillin-tazobactam infusion shorter compare adult achieve appropriate concentration .</brief_summary>
	<brief_title>Safety Pharmacokinetics Piperacillin-tazobactam Extended Infusion Infants Children ( PIP-TAZO )</brief_title>
	<detailed_description>This prospective , open-label Pharmacokinetics safety study piperacillin-tazobactam child 2 months-6y age . Overall goal : To establish extended-infusion piperacillin-tazobactam dosing recommendation infant young child normal renal function , treatment sepsis due resistant organism . Dosing recommendation provide accord different level antibiotic resistance ( MIC ) . We aim establish age threshold extend infusion provide additional therapeutic benefit immature renal function . We also aim describe PK piperacillin-tazobactam standard dose child acute kidney injury . Study population # 1 : Normal Renal Function : Evaluate PK piperacillin-tazobactam extend infusion child 2 months-6y normal renal function . Hypothesis 1.1 : Population clearance piperacillin 20 % low infant 2-5 month compare infant 6-23 month reach adult value 2 year age . Hypothesis 1.2 : Alternative dosing strategy use clinical trial achieve pharmacodynamics ( PD ) target ( 50 % fT &gt; MIC ) minimum inhibitory concentration ( MIC ) 16 mg/L 90 % infant child 2 months-6y . Study Population # 2 : Acute Kidney Injury : Describe PK piperacillin-tazobactam child kidney injury , use standard dosing . Hypothesis 2.1 : Population clearance piperacillin 15 % low infant acute kidney injury normal glomerular filtration rate ( GFR ) . Clearance increase GFR decrease . Screening : Infants child screen use pharmacy software application available institution , display list subject meet inclusion criterion real time . Recruitment take place unit child receive piperacillin-tazobactam . Enrollment/Baseline : Baseline/Pre-Dose Assessment : After determine participant satisfies inclusion exclusion criterion parent legal guardian sign informed consent form , subject assign study number follow evaluation record clinical research form : 1 . Participant demographic include gender , date birth , chronologic age , correct age &lt; 1 year age bear &lt; 37 week gestational age , race , birth weight &lt; 1 year age , weight time consent . 2 . Active clinical diagnosis 3 . Concomitant medication take 72 hour prior first dose piperacillin-tazobactam treatment piperacillin-tazobactam 4 . Laboratory microbiologic determination within 72 hour prior first dose piperacillin-tazobactam 5 . Microbiological result sterile body fluid ( blood , cerebrospinal fluid ( CSF ) , urine obtain catheterization supra-pubic tap ) , within 72 hour prior first dose study drug Assessments/Procedures ( Day 1 Day 14 ) : The following assessment conduct day patient study 1 . Study medication administration : The date time , amount , infusion duration site administration dose record . Day 1 day first dose study drug . 2 . PK sample collection : date time sample collection , total blood volume collect . 3 . Laboratory determination day PK sample collection 4 . Microbiological result sterile body fluid ( blood , CSF , urine obtain catheterization supra-pubic tap ) 5 . Concomitant medication 6. AEs Follow-up ( Day 15 17 End Therapy ) : The following assessment conducted end therapy : 1 . Laboratory determination last day study drug , within 72h last study dose 2. AEs 72h last study dose Laboratory Determinations : Any lab obtain per standard care may record patient study follow timeline : 1 ) within 72 hour prior first dose study medication 2 ) within 72h PK sample collection 3 ) Day 14 therapy ( end therapy , whichever come first ) , within 72h hour last study dose record . If multiple value laboratory obtain 72 hour prior first dose , record value close enrollment . 1 . Any hematology value include hemoglobin , hematocrit , white blood cell count , platelet count , differential . 2 . Any serum chemistry value include blood urea nitrogen ( BUN ) , serum creatinine , potassium , sodium , Aspartate transaminase ( AST ) , Alanine transaminase ( ALT ) , albumin . 3 . Given renal function main determinant piperacillin-tazobactam clearance , serum creatinine obtain prior first study dose , even do per standard care . Microbiological Determinations : All result culture obtain sterile body fluid ( blood , CSF , urine obtain catheterization supra-pubic tap ) 72 hour prior first piperacillin-tazobactam dose final dose piperacillin-tazobactam Day 14 therapy ( whichever come first ) record case report form ( CRF ) . Special Assays Procedures : Pharmacokinetics ( PK ) Samples : During study treatment , 4 plasma PK sample ( 200 µL whole blood/sample ) per subject collect use opportunistic approach ; PK sample collect dose study drug PK piperacillin linear . PK sample obtain time laboratory test collect per routine medical . Specimen Preparation , Handling , Shipping : PK sample collect ethylenediamine-tetra-acetic acid ( EDTA ) microcontainers process immediately place ice processing . Samples identify use preprinted label protocol number . Plasma separate via centrifugation ( 3000g 10 minute 4°C ) , manually aspirate transfer polypropylene tube . Plasma sample frozen -80°C freezer analysis . Once enrollment sample collection complete , PK sample ship dry ice central laboratory piperacillin tazobactam plasma concentration measure use validated bioanalytical assay .</detailed_description>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<criteria>Study population # 1 : Normal renal function Children 2 month 6 year age* Piperacillintazobactam indicate per standard care Informed consent Insufficient venous access allow extend infusion History anaphylaxis βlactams Supported extracorporeal membrane oxygenation ( ECMO ) On renal replacement therapy Cystic fibrosis Acute Kidney injury Chronic renal insufficiency define defined glomerular filtration rate 1060 mL/min/1.73 m2 Study population # 2 : Acute Kidney injury Children 2 month 6 year age Piperacillintazobactam indicate per standard care Informed consent Acute Kidney injury define follow : Doubling serum creatinine accord upper limit normal age gender Doubling baseline serum creatinine ( defined creatinine level admission , value within normal limit age gender ) We wil use small value 2 definition diagnose acute kidney injury give subject . History anaphylaxis βlactams Supported extracorporeal membrane oxygenation ( ECMO ) On renal replacement therapy Cystic fibrosis Chronic renal insufficiency define defined glomerular filtration rate 1060 mL/min/1.73 m2</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Antibiotics</keyword>
	<keyword>Piperacillin-tazobactam</keyword>
	<keyword>Resistant bacteria</keyword>
</DOC>